The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The depressed company could use Mylotarg as a stepping stone in AML.
It’s back to school for biotech, with a packed conference schedule.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
Bicara and DualityBio will soon test market appetite for new oncology issues.
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
